KAIROS PHARMA, LTD. Preferred Stock, Par or Stated Value Per Share
KAIROS PHARMA, LTD. (KAPA) had Preferred Stock, Par or Stated Value Per Share of $0.00 per share as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Stockholders' Equity, Number of Shares, Par Value and Other Disclosure › Preferred Stock, Number of Shares, Par Value and Other Disclosure
us-gaap:PreferredStockParOrStatedValuePerShare · last filed 2026-08-12
- 2026-06-30: Preferred Stock, Par or Stated Value Per Share $0.00.
- 2026-03-31: Preferred Stock, Par or Stated Value Per Share $0.00.
- 2025-12-31: Preferred Stock, Par or Stated Value Per Share $0.00.
- 2025-09-30: Preferred Stock, Par or Stated Value Per Share $0.00.
| Period end | Preferred Stock, Par or Stated Value Per Share |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-12 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-12 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-14 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-12 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-14 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-31 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 |
| 2023-12-31 | $0.00 10-K · filed 2025-04-15 |
| 2023-05-10 | $0.00 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |